Core Clinical Molecular Diagnostics Market Trends, Drivers and Key Developments (2024 - 2034)

Answer : According to Precedence Research, the global In Vitro Diagnostics (IVD) market was registered revenue around US$ 65.4 billion in 2019 and is expected to reach US$ 85.23 billion by 2027.

Answer : The global In Vitro Diagnostics (IVD) market is exhibiting a compound annual growth rate (CAGR) of around 5% from 2021 to 2027.

Answer : In recent years, in vitro diagnostics industry has recognized significant developments. Rising geriatric population, prevalence of infectious as well as chronic diseases and existence of automated in vitro diagnosis systems for hospitals to offer precise diagnosis are some of the factors are expected to propel the growth of the market. Thus, growing elderly population and subsequent demand for immunoassay-based tests flourishes the market growth. Additionally, increased government funding and other healthcare organizations investment into in vitro diagnostics market is the key drivers to boost market growth over the forecast period. Growing consciousness on personalized medicines and increasing acceptance of point-of-care testing are also high impact rendering market drivers.

Answer : The reagent segment dominated the market in 2019 as reagents are indispensible part of every in vitro diagnostics test. Rising demand for point-of-care tests and self tests and increasing various R&D initiatives are projected to accelerate the growth of this segment.

Answer : North America is estimated to top the global market throughout the estimated time period due to high-rise in healthcare awareness among population and its well penetrated healthcare system.

Answer : Asia Pacific is projected to witness fastest CAGR in the in vitro diagnostics market over the forecast period. The growth in Asia Pacific has been attributed to the increasing healthcare spending and growing prevalence of diabetes in the region.

Answer : The immunoassay dominated the global in vitro diagnostics market in 2019 owing to growing adoption of immunoassay based rapid testing and POC testing.